Speciality chemicals group Elementis is continuing a £25m share buyback after first-half results showed a sharp rise in profit and margins under its Elevate Elementis strategy.

Elementis (LSE:ELM), the FTSE 250 speciality chemicals company best known for its rheology additives used in coatings and personal care products, has been buying back its own shares almost daily since early August, with the latest repurchase notice filed on 12 October 2026. The programme, worth about £25m, is funded from the proceeds of the sale of its pharmaceutical manufacturing business and follows a set of half-year results that pointed to improving profitability.

Margins move higher

For the six months to 30 June 2026, Elementis (LSE:ELM) reported revenue of $318.2m, up 9.4% on a reported basis and 4.7% on an organic constant currency basis. Adjusted operating profit rose 16.4% to $73.2m, or 9.8% on an organic basis, and the adjusted operating margin widened to 23.0% from 21.6% a year earlier. Adjusted diluted earnings per share climbed 28.8% to 8.5 cents, while statutory diluted earnings per share from continuing operations rose 31.6% to 7.5 cents.

Both divisions contributed. Personal Care revenue increased 2.9% organically to $109.2m, delivering adjusted operating profit of $41.6m at a margin of 38.1%. Coatings, the larger division, grew revenue 5.6% organically to $209.0m, with adjusted operating profit of $43.2m and a margin of 20.7%. The board raised the interim dividend by 15.4% to 1.5 cents per share.

Chief executive Luc van Ravenstein said the results showed real progress coming through in the financial numbers, one year into the Elevate Elementis strategy.

Balance sheet strengthens

The group's financial position has also improved. Net debt fell to $163.8m at 30 June from $185.4m at the end of 2025, taking leverage down to 1.1 times EBITDA from 1.3 times. That gave the board room to launch the buyback while continuing to invest in innovation and its more profitable product lines.

Elementis has spent recent years reshaping its portfolio, including the disposal of its talc business, in order to focus on higher-margin additives. The strategy aims to deliver steady margin expansion and more consistent cash generation, and the first-half figures suggest that is starting to come through. Organic growth of under 5% shows that much of the profit improvement came from pricing, mix and cost discipline rather than volume alone, which management regards as evidence that the business can grow earnings even in subdued markets. Reported growth was also notably higher than organic growth, underlining the influence of factors outside underlying trading on the headline numbers.

Board changes and outlook

On 16 September 2026, the company confirmed Christine Soden as Senior Independent Director with immediate effect. She had been serving in the role on an interim basis since March. A separate director share dealing was disclosed the same day.

Looking ahead, Elementis said it expects full-year performance to be in line with expectations. Company-compiled consensus points to adjusted operating profit of $132.5m for 2026, within a range of $129.4m to $136.5m. Management has, however, said it is monitoring risks linked to the conflict in the Middle East, which could affect energy prices, raw material costs and demand in some end markets.

The wider chemicals sector has been under pressure from soft industrial demand in Europe and uncertainty over global trade, which makes Elementis' margin progress notable against that backdrop. Investors will watch for confirmation of second-half trading momentum and progress on the buyback when the company next updates the market.